Statins and prostate cancer: Molecular and clinical aspects

European Journal of Cancer

Volumn 47, Issue 6, 2011, Pages 819-830

  Papadopoulos, Georgios ^a   Delakas, Dimitrios ^a   Nakopoulou, Lydia ^b   Kassimatis, Theodoros ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

HMG CoA reductase inhibitors; Isoprenoids; Lipid rafts; Prostate cancer; PSA; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CARCINOGENESIS; HUMAN; LIPID RAFT; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; REVIEW; TUMOR VASCULARIZATION;

ANTICARCINOGENIC AGENTS; EARLY DETECTION OF CANCER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEMBRANE MICRODOMAINS; META-ANALYSIS AS TOPIC; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79952984219     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.01.005     Document Type: Article

References (133)

1. P.R. Hebert, J.M. Gaziano, K.S. Chan, and C.H. Hennekens Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials JAMA 278 4 1997 313 321 (Pubitemid 27339660)
2. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 6257 1990 425 430
3. R. Collins, J. Armitage, S. Parish, P. Sleigh, R. Peto Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial Lancet 361 9374 2003 2005 2016
4. C. Becker, and C.R. Meier Statins and the risk of Parkinson's disease: an update on the controversy Expert Opin Drug Saf 8 3 2009 261 271
5. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 9242 2000 1627 1631
6. T.I. Kassimatis, and A. Agrafiotis Chronic kidney disease: implications of the AURORA and JUPITER results Nat Rev Nephrol 6 11 2010 636 637
7. T.I. Kassimatis, and P.A. Konstantinopoulos The role of statins in chronic kidney disease (CKD): friend or foe? Pharmacol Ther 122 3 2009 312 323
8. D.W. McCarey, I.B. McInnes, and R. Madhok Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial Lancet 363 9426 2004 2015 2021 (Pubitemid 38781100)
9. J. Yue, X. Zhang, B. Dong, and M. Yang Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials Menopause 17 5 2010 1071 1079
10. K.K. Chan, A.M. Oza, and L.L. Siu The statins as anticancer agents Clin Cancer Res 9 1 2003 10 19 (Pubitemid 36109711)
11. A. Sassano, and L. Platanias Statins in tumor suppression Cancer Lett 260 1-2 2008 11 19
12. W.W.-L. Wong, M.M. Tan, and Z. Xia Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin Clin Cancer Res 7 7 2001 2067 2075 (Pubitemid 32994846)
13. J. Dulak, and A. Jozkowicz Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy Curr Cancer Drug Targets 5 8 2005 579 594 (Pubitemid 41789598)
14. C. Denoyelle, M. Vasse, and M. Körner Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasivness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study Carcinogenesis 22 8 2001 1139 1148 (Pubitemid 32737327)
15. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 2010 765 781
16. T.J. Murtola, T.L. Tammela, and L. Määttänen Prostate cancer and PSA among statin users in the Finnish Prostate cancer screening trial Int J Cancer 127 7 2010 1650 1659
17. M.R. Graaf, A.B. Beiderbeck, A.C. Egberts, D.J. Richel, and H.J. Guchelaar The risk of cancer in users of statins J Clin Oncol 22 12 2004 2388 2394 (Pubitemid 41115396)
18. J. Haukka, R. Sankila, and T. Klaukka Incidence of cancer and statin usage-record linkage study Int J Cancer 126 1 2010 279 284
19. Y.C. Li, M.J. Park, S.-K. Ye, C.-W. Kim, and Y.-N. Kim Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents Am J Pathol 168 4 2006 1107 1118
20. K. Simons, and D. Toomre Lipid rafts and signal transduction Nat Rev Mol Cell Biol 1 1 2000 31 39
21. M.R. Freeman, B. Cinar, and M.L. Lu Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer Trends Endocrinol Metab 16 6 2005 273 279 (Pubitemid 41058759)
22. G. Yang, L.D. Truong, and T.L. Timme Elevated expression of caveolin is associated with prostate and breast cancer Clin Cancer Res 4 8 1998 1873 1880 (Pubitemid 28369170)
23. L. Li, G. Yang, and S. Ebara Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells Cancer Res 61 11 2001 4386 4392 (Pubitemid 32685764)
24. T.M. Williams, G.S. Hassan, and J. Li Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice J Biol Chem 280 26 2005 25134 25145 (Pubitemid 40934606)
25. D.D. Di Vizio, F. Sotgia, and T.M. Williams Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression Cancer Biol Ther 6 8 2007 1263 1268 (Pubitemid 351590381)
26. J.V. Swinnen, T. Roskams, and S. Joniau Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer Int J Cancer 98 1 2002 19 22 (Pubitemid 34113412)
27. J.V. Swinnen, F. Vanderhoydonc, and A.A. Elgamal Selective activation of the fatty acid synthsesis pathway in human prostate cancer Int J Cancer 88 2 2000 176 179
28. J.V. Swinnen, P.P. Van Veldhoven, and L. Timmermans Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains Biochem Biophys Res Commun 302 4 2003 898 903 (Pubitemid 36294061)
29. F.P. Kuhajda Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology Nutrition 16 3 2000 202 208 (Pubitemid 30114274)
30. T. Van de Sande, E. De Schrijver, and W. Heyns Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells Cancer Res 62 3 2002 642 646 (Pubitemid 34126933)
31. D.A. Altomare, and J.R. Testa Perturbations of the Akt signaling pathway in human cancer Oncogene 24 50 2005 7455 7464 (Pubitemid 41637985)
32. M.L. Lu, M.C. Schneider, Y. Zheng, X. Zhang, and J.P. Richie Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation J Biol Chem 276 16 2001 13442 13451
33. B. Cinar, N.K. Mukhopadhyay, G. Meng, and M.R. Freeman Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains J Biol Chem 282 40 2007 29584 29593 (Pubitemid 350043392)
34. L. Li, C.H. Ren, S.A. Tahir, C. Ren, and T.C. Thompson Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2 Mol Cell Biol 23 24 2003 9389 9404 (Pubitemid 37499824)
35. L. Zhuang, J. Kim, R.M. Adam, K.R. Solomon, and M.R. Freeman Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts J Clin Invest 115 4 2005 959 968 (Pubitemid 40489400)
36. C. Mineo, G.N. Gill, and R.G. Anderson Regulated migration of epidermal growth factor receptor from caveolae J Biol Chem 274 43 1999 30636 30643
37. H.Y. Oh, E.J. Lee, and S. Yoon Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cels through EGFR-mediated Akt and ERK signal transduction Prostate 67 10 2007 1061 1069 (Pubitemid 46991915)
38. H.Y. Oh, J. Leem, S.J. Yoon, S. Yoon, and S.J. Hong Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/ p70S6k pathway and down-regulation of androgen receptor Biochem Biophys Res Commun 393 2 2010 319 324
39. L. Zhuang, J. Lin, M.L. Lu, K.R. Solomon, and M.R. Freeman Cholesterol-rich lipid rafts mediated Akt-regulated survival in prostate cancer cells Cancer Res 62 8 2002 2227 2231 (Pubitemid 34411694)
40. P.A. Konstantinopoulos, M.V. Karamouzis, and A.G. Papavassiliou Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets Nat Rev Drug Discov 6 7 2007 541 555 (Pubitemid 47019443)
41. C.Y. Wang, O.Y. Liu, and J.K. Liao Pleiotropic effects of statin therapy: molecular mechanisms and clinical results Trends Mol Med 14 1 2008 37 44
42. D.M. Peehl Oncogenes in prostate cancer. An update Cancer 71 3 Suppl 1993 1159 1164
43. M.J. Weber, and D. Gioeli Ras signaling in prostate cancer progression J Biol Chem 91 1 2004 13 25
44. J.K. Liao, M. Seto, and K. Noma Rho kinase (ROCK) inhibitors J Cardiovasc Pharmacol 50 1 2007 17 24 (Pubitemid 47220442)
45. K. Pruitt, and C.J. Der Ras and Rho regulation of the cell cycle and oncogenesis Cancer Lett 171 1 2001 1 10 (Pubitemid 32727350)
46. S. Aznar, P. Fernández-Valerón, C. Espina, and J.C. Lacal Rho GTPases: potential candidates for anticancer therapy Cancer Lett 206 2 2004 181 191 (Pubitemid 38317288)
47. J.W. Harbour, and D.C. Dean The Rb/E2F pathway: expanding roles and emerging paradigms Genes Dev 14 19 2000 2393 2409
48. H. Gille, and J. Downward Multiple ras effector pathways contribute to G(1) cell cycle progression J Biol Chem 274 31 1999 22033 22040
49. M.R. Graaf, D.J. Richel, C.J.F. van Noorden, and H.J. Guchelaar Effects of statins and farnesytransferase inhibitors on the development and progression of cancer Cancer Treat Rev 30 7 2004 609 641 (Pubitemid 39451828)
50. J.T. Lee, B.D. Lehmann, and D.M. Terrian Targeting prostate cancer based on signal transduction and cell cycle pathways Cell cycle 7 12 2008 1745 1762 (Pubitemid 351988740)
51. J. Lee, I. Lee, C. Park, and W.K. Kang Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Biochem Biophys Res Commun 339 3 2006 748 754 (Pubitemid 41772877)
52. P.M. Ghosh, N. Ghosh-Choudhury, and M.L. Moyer Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line Oncogene 18 28 1999 4120 4130 (Pubitemid 29363919)
53. A. Parikh, C. Childress, and K. Deitrick Statin-induced autophagy by inhibition of gearanylgeranyl biosynthesis in prostate cancer PC3 cells Prostate 70 9 2010 971 981
54. A. Hoque, H. Chen, and X.C. Xu Statin induces apoptosis and cell growth arrest in prostate cancer cells Cancer Epidemiol Biomarkers Prev 17 1 2008 88 94 (Pubitemid 351196277)
55. M. Marcelli, G.R. Cunningham, and S.J. Haidacher Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP Cancer Res 58 1 1998 76 83 (Pubitemid 28027720)
56. L. Yang, Y. Wang, T.J. Lv, L.Q. Zhou, and J. Jin Effects of clinically effective dose of lovastatin on prostate cancer PC3 cells Beijing Da Xue Xue Bao 42 4 2010 391 395
57. WAF1/CIP1 in human prostate carcinoma cells J Biol Chem 17 24 1998 10618 10623 (Pubitemid 28227674)
58. U. Sivaprasad, T. Abbas, and A. Dutta Differential efficacy of 3-hydroxy-3-methulglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells Mol Cancer Ther 5 9 2006 2310 2316 (Pubitemid 44530468)
59. C. Park, I. Lee, and W.K. Kang Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death Carcinogenesis 22 10 2001 1727 1731 (Pubitemid 32952154)
60. C. Ukomadu, and A. Dutta Inhibition of cdk2 activating phosphorylation by mevastatin J Biol Chem 278 7 2003 4840 4846 (Pubitemid 36800989)
61. M.A. Shibata, C. Kavanaugh, and E. Shibata Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models Carcinogenesis 24 3 2003 453 459 (Pubitemid 36432640)
62. H. Hartog, J. Wesseling, H.M. Boezen, and W.T. van der Graaf The insulin-like growth factor 1 receptor in cancer: old focus, new future Eur J Cancer 43 13 2007 1895 1904 (Pubitemid 47284866)
63. Y. Sekine, Y. Furuya, and M. Nishii Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor BBRC 372 2 2008 356 361
64. A.G. Renehan, M. Zwahlen, and C. Minder Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 9418 2004 1346 1353 (Pubitemid 38529873)
65. M. Weis, C. Heeschen, A.J. Glassford, and J.P. Cooke Statins have biphasic effects on angiogenesis Circulation 105 6 2002 739 745 (Pubitemid 34157379)
66. Q. Zhou, and J.K. Liao Pleiotropic effects of statins. Basic research and clinical perspectives Circ J 74 5 2010 818 826
67. 2+ sensitization Circ Res 91 2 2002 83 84
68. C.D. Searles, L. Ide, M.E. Davis, H. Cai, and M. Weber Actin cytoskeleton organization and posttranscriptional regulation of endothelial nitric oxide synthase during cell growth Circ Res 95 5 2004 488 495 (Pubitemid 39180929)
69. U. Laufs, and J.K. Liao Post-transcriptional regulation of endothelial nitric oxide synthase Mrna stability by Rho GTPase J Biol Chem 273 37 1998 24266 24271 (Pubitemid 28435775)
70. C. Wang, W. Tao, and Y. Wang Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer Eur Urol 58 3 2010 418 426
71. S. Sutcliffe, and E.A. Platz Inflammation in the etiology of prostate cancer: an epidemiologic perspective Urol Oncol 25 3 2007 242 249 (Pubitemid 46680518)
72. L.L. Bañez, J.C. Klink, and J. Jayachandran Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy Cancer Epidemiol Biomarkers Prev 19 3 2010 722 728
73. K. Mausner-Fainberg, G. Luboshits, and A. Mor The effect of HMG-CoA reductase inhibitors on naturally occurring CD+CD25+ T cells Atherosclerosis 197 2 2008 829 839 (Pubitemid 351417882)
74. Z. Mallat, H. Ait-Oufella, and A. Tedgui Regulatory T cell responses: potential role in the control of atherosclerosis Curr Opin Lipidol 16 5 2005 518 524 (Pubitemid 41376901)
75. T. Aprahamian, R. Bonegio, and J. Rizzo Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model J Immunol 177 5 2006 3028 3034 (Pubitemid 44277819)
76. C. Weber, W. Erl, K.S. Weber, and P.C. Weber HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia J Am Coll Cardiol 30 5 1997 1212 1217
77. G. Weitz-Schmidt, K. Welzenbach, and V. Brinkmann Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat Med 7 6 2001 687 692 (Pubitemid 32588024)
78. H. Usui, K. Shikata, and M. Matsuda HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats Nephrol Dial Transplant 18 2 2003 265 272 (Pubitemid 36181675)
79. M. Sugiyama, M. Ohashi, H. Takase, K. Sato, R. Ueda, and Y. Dohi Effects of atorvastatin on inflammation and oxidative stress Heart Vessels 20 4 2005 133 136 (Pubitemid 41031009)
80. P. Gelosa, M. Cimino, and A. Pignieri The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation Vasc Health Risk Manag 3 5 2007 567 577 (Pubitemid 350104113)
81. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 12 2000 1399 1402 (Pubitemid 32001026)
82. M. Romano, L. Diomede, and M. Sironi Inhibition of monocyte chemotactic protein-1 synthesis by statins Lab Invest 80 7 2000 1095 1100 (Pubitemid 30483228)
83. R. Paumelle, and B. Staels Peroxisome proliferator-activated receptors mediate pleiotropic actions of statins Circ Res 100 10 2007 1394 1395 (Pubitemid 46834749)
84. L. Michalik, B. Desvergne, and W. Wahli Peroxisome-proliferator-activated receptors and cancers: complex stories Nat Rev Cancer 4 1 2004 61 70 (Pubitemid 38082154)
85. Zheng X, Cui XX, Avila GE, et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007;13(18 Pt 1):5480-7. (Pubitemid 47510376)
86. T.J. Murtola, P. Pennanen, and H. Syvälä Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations Prostate 69 9 2009 1017 1023
87. C.J. Yao, G.M. Lai, and C.F. Chan Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone Int J Cancer 118 3 2006 773 779
88. K. Hindler, C.S. Cleeland, E. Rivera, and C.D. Collard The role of statins in cancer therapy Oncologist 11 3 2006 306 315
89. A.A. Schmitz, E.E. Govek, B. Böttner, and L. Van Aelst Rho GTPases: signaling, migration and invasion Exp Cell Res 261 1 2000 1 12
90. T. Nbel, W. Dippold, H. Kleinert, B. Kaina, and G. Fritz Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion FASEB J 18 1 2004 140 142
91. I.K. Wang, S.Y. Lin-Shiau, and J.K. Lin Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation Oncology 59 3 2000 245 254
92. T. Kusama, M. Mukai, and T. Iwasaki Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Cancer Res 61 12 2001 4885 4891 (Pubitemid 32691906)
93. M.R. Goldstein, L. Mascitelli, and F. Pezzetta How statins may increase prostate cancer Cancer Epidemiol Biomarkers Prev 17 2 2008 459 (Pubitemid 351272801)
94. A.M. Miller, K. Lundberg, and V. Ozenci CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients J Immunol 177 10 2006 7398 7405 (Pubitemid 44715110)
95. I. Ford, H. Murray, and C.J. Packard N Engl J Med 357 15 2007 1477 1486
96. Y. Kureishi, Z. Luo, and I. Shiojima The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 9 2000 1004 1010
97. O. Feron, C. Dessy, J.P. Desager, and J.L. Balligand Hydroxy- methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance Circulation 103 1 2001 113 118 (Pubitemid 32050445)
98. D.H. Walter, S. Dimmeler, and A.M. Zeiher Effects of statins on endothelium and endothelial progenitor cell recruitment Semin Vasc Med 4 4 2004 385 393 (Pubitemid 40577827)
99. P.J. van Leeuwen, D. Connolly, and A. Gavin Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit Eur J Cancer 46 2 2010 377 383
100. J.S. Benner, R.J. Glynn, and H. Mogun Long-term persistence in use of statin therapy in elderly patients JAMA 288 4 2002 455 461 (Pubitemid 34787476)
101. T.J. Murtola, T. Visakorpi, J. Lahtela, H. Syvälä, and T.L.J. Tammela Statins and prostate cancer prevention: where we are now, and future directions Nat Clin Pract Urol 5 7 2008 376 387
102. P.F. Coogan, L. Rosenberg, and B.L. Strom Statin use and the risk of 10 cancers Epidemiology 18 2 2007 213 219
103. L. Blais, A. Desgagné, and J. LeLorier 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study Arch Intern Med 160 15 2000 2363 2368
104. S. Friis, A.H. Poulsen, and S.P. Johnsen Cancer risk among statin users: a population-based cohort study Int J Cancer 114 4 2005 643 647 (Pubitemid 40349625)
105. J.A. Kaye, and H. Jick Statin use and cancer risk in the General Practice Research Database Br J Cancer 90 3 2004 635 637 (Pubitemid 38297203)
106. T.J. Murtola, T.L.V. Tammela, J. Lahtela, and A. Auvinen Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control staudy Cancer Epidemiol Biomarkers Prev 16 11 2007 2226 2232 (Pubitemid 351196353)
107. J. Shannon, S. Tewoderos, and M. Garzotto Statins and prostate cancer risk: a case-control study Am J Epidemiol 162 4 2005 318 325 (Pubitemid 41389713)
108. E.A. Platz, M.F. Leitzmann, and K. Visvanathan Statin drugs and risk of advanced prostate cancer J Natl Cancer Inst 98 24 2006 1819 1825 (Pubitemid 46017933)
109. E.J. Jacobs, C. Rodriguez, and E.B. Bain Colesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort Cancer Epidemiol Biomarkers Prev 16 11 2007 2213 2217 (Pubitemid 351196351)
110. W.R. Farwell, R.E. Scranton, and E.V. Lawler The association between statins and cancer incidence in a veterans population J Natl Cancer Inst 100 2 2008 134 139 (Pubitemid 351480564)
111. G.D. Friedman, E.D. Flick, and N. Udaltsova Screening statins for possible carcinogenic risk; up to 9 years of follow-up of 361 859 recipients Pharmacoepidemiol Dug Saf 17 1 2008 27 36 (Pubitemid 351166615)
112. E.D. Flick, L.A. Habel, and K.A. Chan Statin use and risk of prostate cancer in the California Men's Health Study Cohort Cancer Epidemiol Biomarkers Prev 16 11 2007 2218 2225 (Pubitemid 351196352)
113. R.H. Breau, R.J. Karnes, and D.J. Jacobson The association between statin use and the diagnosis of prostate cancer in a population based cohort J Urol 184 2 2010 494 500
114. D.M. Boudreau, O. Yu, D.S. Buist, and D.L. Miglioretti Statin use and prostate cancer risk in a large population-based setting Cancer Causes Control 19 7 2008 767 774
115. I. Agalliu, C.A. Salinas, P.D. Hansten, E.A. Ostrander, and J.L. Stanford Statin use and risk of prostate cancer: results from a population-based epidemiologic study Am J Epidemiol 168 3 2008 250 260 (Pubitemid 352019786)
116. C.L. Amling Relationship between obesity and prostate cancer Curr Opin Urol 15 3 2005 167 171 (Pubitemid 40586176)
117. C. Baigent, A. Keech, and P.M. Kearney Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins Lancet 366 9493 2005 1267 1278
118. K.M. Dale, C.I. Coleman, and N.N. Henyan Statins and cancer risk: a meta-analysis JAMA 295 1 2006 74 80 (Pubitemid 43042692)
119. D.R. Browning, and R.M. Martin Statins and risk of cancer: a systematic review and metaanalysis Int J Cancer 120 4 2006 833 843
120. J. Kuoppala, A. Lamminpää, and E. Pukkala Statins and cancer: a systematic review and meta-analysis Eur J Cnacer 44 15 2008 2122 2132
121. M.L. Taylor, B.J. Wells, and M.J. Smolak Statins and cancer: a meta-analysis of case-control studies Eur J Cancer Prev 17 3 2008 259 268 (Pubitemid 351549667)
122. S. Bonovas, K. Filioussi, and N.M. Sitaras Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies Int J Cancer 123 4 2008 899 904 (Pubitemid 352032419)
123. L.S. Krane, S.A. Kaul, and H.J. Stricker Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen J Urol 183 1 2010 118 124
124. Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis. 2010 Oct 12 Epub ahead of print.
125. R.J. Hamilton, L.L. Banez, and W.J. Aronson Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database Cancer 116 14 2010 3389 3398
126. D.E. Soto, S. Daignault, H.M. Sandler, and M.E. Ray No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer Urology 73 1 2009 158 162
127. R. Gutt, N. Tonlaar, and R. Kunnavakkam Statin use and risk of prostate cancer recurrence in men treated with radiation therapy J Clin Oncol 28 16 2010 2653 2659
128. M.A. Kollmeier, M.S. Katz, and K. Mak Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy Int J Radiat Oncol Biol Phys 79 3 2011 713 718
129. H.Y. Pan, A.R. DeVault, D. Wang-Iverson, E. Ivashkiv, B.N. Swanson, and A.A. Sugerman Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin J Clin Pharmacol 30 12 1990 1128 1135
130. J. Martínez-Botas, A.J. Ferruelo, Y. Suárez, C. Fernández, D. Gómez-Coronado, and M.A. Lasunción Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives Biochim Biophys Acta 1532 3 2001 185 194 (Pubitemid 32706438)
131. M.H. Hager, K.R. Solomon, and M.R. Freeman The role of cholesterol in Prostate cancer Curr Opin Clin Nutr Metab Care 9 4 2006 379 385 (Pubitemid 44097806)
132. M.A. Moyad, and P.R. Carrolkl Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am 31 2 2004 289 300 (Pubitemid 38584594)
133. M.A. Moyad Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I Urol Oncol 22 6 2004 466 471 (Pubitemid 43193735)